On the basis of these past studies, our research innovatively compared the prognostic impact of all six family members in prostate cancer and found that PRDX5 has the strongest predictive value for poor prognosis in PCa patients and is most closely associated with adverse outcomes. Here, PRDX5 is linked to prostate cancer.